Form 4 for NVAX NOVAVAX INC
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001209191-24-002239 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-25 | 2024-01-23 | NVAX | Jacobs John C | Pres, CEO, Dir | M - OptEx | — | +83.2K | 83.2K | New | — |
| D | 2024-01-25 | 2024-01-23 | NVAX | Jacobs John C | Pres, CEO, Dir | F - Tax | $4.26 | -40.1K | 43.1K | -48% | -$170.8K |
| D | 2024-01-25 | 2024-01-23 | NVAX | Jacobs John C | Pres, CEO, Dir | M - OptEx | $0.00 | -83.2K | 166.4K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | M | A | 83,197 | — | 83,197 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| 2 | Common | Common Stock | 2024-01-23 | F | D | 40,093 | $4.26 | 43,104 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-01-23 | M | D | 83,197 | $0.00 | 166,393 | D | — · — to — | 83,197 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. (F2) The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date. |